JP2002531539A - イオンチャネル調節剤 - Google Patents

イオンチャネル調節剤

Info

Publication number
JP2002531539A
JP2002531539A JP2000586677A JP2000586677A JP2002531539A JP 2002531539 A JP2002531539 A JP 2002531539A JP 2000586677 A JP2000586677 A JP 2000586677A JP 2000586677 A JP2000586677 A JP 2000586677A JP 2002531539 A JP2002531539 A JP 2002531539A
Authority
JP
Japan
Prior art keywords
group
disease
oxime
formula
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000586677A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002531539A5 (https=
Inventor
ジェンセン・ボー・スカーニング
クリストファーセン・パルレ
ストロベック・ドルテ
トイバー・レネ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NTG Nordic Transport Group AS
Original Assignee
Neurosearch AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurosearch AS filed Critical Neurosearch AS
Publication of JP2002531539A publication Critical patent/JP2002531539A/ja
Publication of JP2002531539A5 publication Critical patent/JP2002531539A5/ja
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/32Oximes
    • C07C251/34Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C07C251/48Oximes with oxygen atoms of oxyimino groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with the carbon atom of at least one of the oxyimino groups bound to a carbon atom of a six-membered aromatic ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/14Drugs for dermatological disorders for baldness or alopecia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Surface Acoustic Wave Elements And Circuit Networks Thereof (AREA)
  • Transmitters (AREA)
JP2000586677A 1998-12-04 1999-12-03 イオンチャネル調節剤 Pending JP2002531539A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DK199801609 1998-12-04
DKPA199801609 1998-12-04
PCT/DK1999/000680 WO2000034228A1 (en) 1998-12-04 1999-12-03 Ion channel modulating agents

Publications (2)

Publication Number Publication Date
JP2002531539A true JP2002531539A (ja) 2002-09-24
JP2002531539A5 JP2002531539A5 (https=) 2007-02-01

Family

ID=8106516

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000586677A Pending JP2002531539A (ja) 1998-12-04 1999-12-03 イオンチャネル調節剤

Country Status (7)

Country Link
US (1) US6458846B1 (https=)
EP (1) EP1133467B1 (https=)
JP (1) JP2002531539A (https=)
AT (1) ATE276232T1 (https=)
AU (1) AU1549700A (https=)
DE (1) DE69920259T2 (https=)
WO (1) WO2000034228A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007503466A (ja) * 2003-05-16 2007-02-22 ワイス アリール−カルボアルデヒドオキシム誘導体およびエストロゲン様物質としてのその使用
JP2007503468A (ja) * 2003-05-19 2007-02-22 アイアールエム・リミテッド・ライアビリティ・カンパニー 免疫抑制化合物および組成物

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DZ3401A1 (fr) 2000-07-19 2002-01-24 Warner Lambert Co Esters oxygenes d'acides 4-iodophenylamino benzhydroxamiques
CA2433041A1 (en) * 2000-12-28 2002-07-11 Switch Biotech Aktiengesellschaft Use of intermediate-conductance potassium channels and modulators for diagnosing and treating diseases involving disturbed keratinocyte activiyty
DE10250870A1 (de) * 2002-10-31 2004-05-13 Switch Biotech Ag Zusammensetzung enthaltend Aktivatoren von IK-Kaliumkanälen und Calcineurin-Antagonisten und deren Verwendung
WO2005040098A1 (en) 2003-10-21 2005-05-06 Warner-Lambert Company Llc Polymorphic form of n-[(r)-2,3-dihydroxy-propoxy]-3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-benzamide
WO2006115509A2 (en) 2004-06-24 2006-11-02 Novartis Vaccines And Diagnostics Inc. Small molecule immunopotentiators and assays for their detection
WO2011094416A1 (en) 2010-01-27 2011-08-04 Purdue Research Foundation Substituted norindenoisoquinolines, syntheses thereof, and methods of use
PL227238B1 (pl) * 2015-03-02 2017-11-30 Politechnika Warszawska Sposób wytwarzania 5-alkilosalicylaldoksymów i zastosowanie
CN114262282B (zh) * 2021-12-16 2024-04-19 广东省科学院资源利用与稀土开发研究所 一种醛肟类化合物及其制备方法和应用
WO2025026555A1 (en) * 2023-08-02 2025-02-06 Universidad Pública de Navarra Aldoximes as no donors, and their uses as plant architecture modifiers and in therapy

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4347372A (en) * 1978-09-01 1982-08-31 Ciba-Geigy Corporation Benzoxazolyl-glyoxylonitrile-2-oxime ether derivatives
DD235450B1 (de) * 1983-12-29 1988-02-03 Humboldt Uni Z Berlin Verfahren zur herstellung neuer 1-(2-hydroxyaryl)-alkan-1-on-oxime
GB8617648D0 (en) * 1986-07-18 1986-08-28 Ici Plc Fungicides
WO1995001157A1 (en) * 1993-06-29 1995-01-12 The Procter & Gamble Company Use of hydroxyphenyl oximes as chelating photoprotectants
US5840758A (en) * 1996-06-06 1998-11-24 Abbott Laboratories Oxime derivatives of fenamates as inhibitors of prostaglandin biosynthesis
US6503947B1 (en) * 1998-01-27 2003-01-07 Brigham And Women's Hospital Method of treating cytotoxic damage

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007503466A (ja) * 2003-05-16 2007-02-22 ワイス アリール−カルボアルデヒドオキシム誘導体およびエストロゲン様物質としてのその使用
JP2007503468A (ja) * 2003-05-19 2007-02-22 アイアールエム・リミテッド・ライアビリティ・カンパニー 免疫抑制化合物および組成物
JP2011012069A (ja) * 2003-05-19 2011-01-20 Irm Llc 免疫抑制化合物および組成物
US7939519B2 (en) 2003-05-19 2011-05-10 Novartis Ag Immunosuppresant compounds and compositions

Also Published As

Publication number Publication date
US20020058700A1 (en) 2002-05-16
EP1133467A1 (en) 2001-09-19
ATE276232T1 (de) 2004-10-15
DE69920259D1 (de) 2004-10-21
WO2000034228A1 (en) 2000-06-15
EP1133467B1 (en) 2004-09-15
US6458846B1 (en) 2002-10-01
AU1549700A (en) 2000-06-26
DE69920259T2 (de) 2005-01-20

Similar Documents

Publication Publication Date Title
JP2002531552A (ja) イオンチャネル調節剤としての新規ベンズイミダゾロン−、ベンズオキサゾロン−又はベンゾチアゾロン−誘導体
JP2002531498A (ja) イオンチャネル活性剤としてのイサチン誘導体の使用方法
JP2002533318A (ja) イオンチャネル調節剤
EP3445756A1 (en) Compounds and compositions for treating conditions associated with nlrp activity
JP4966958B2 (ja) カリウムチャネル調節剤及び医療における使用
UA111963C2 (uk) ПОХІДНІ (1,2,4)ТРИАЗОЛО[4,3-a]ХІНОКСАЛІНУ ЯК ІНГІБІТОРИ ФОСФОДІЕСТЕРАЗ
JP2002531539A (ja) イオンチャネル調節剤
EP4410786A1 (en) Sulfonamide compound, preparation method therefor and use thereof
JP2008534472A (ja) カリウムチャンネル調節剤としてのピラゾリル−ピリミジン及びその医学的使用
JP2000501432A (ja) 新規インドール―2,3―ジオン―3―オキシム誘導体
TW202332439A (zh) p38 MAPK/MK2通路調節劑及其組合物、製備方法和用途
TW202334119A (zh) p38 MAPK/MK2通路調節劑及其組合物、製備方法和用途
JP5868994B2 (ja) Katii阻害剤
JP2002544268A (ja) イオンチャネル調節剤
KR20210125982A (ko) 신경변성 질환의 치료를 위한 2-플루오린화된 담즙산
EP1187610A2 (en) Use of ion channel modulating agents
JP2008509111A (ja) 2−アミノベンズイミダゾール誘導体及び小コンダクタンスカルシウム依存性カリウムチャネルのモジュレーターとしてのその使用
RU2858200C2 (ru) Ароматическое гетероциклическое соединение с конденсированным кольцом в качестве регулятора калиевых каналов, способ его получения и применение
TW202540104A (zh) 作為n-蛋白抑制劑之苯二氮平化合物
HK1146934A1 (en) Modulators of cystic fibrosis transmembrane conductance regulator

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20061130

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20061130

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20090325

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090428

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20091027